1Alexandrakis MG, Moschandrea JA, Koulocheri SA, et al. Discrimination between malignant and nonmalignant ascites using serum and ascitic fluid proteins in a multivariate analysis model [J]. Dig Dis Sci, 2000,45(3) : 500-508.
2Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase 1 study of intrapleural batimastat(BB-gg), a matrix metallopmteinase inhibitor, in the treatment of malignant pleural effusions [J]. Clin Cancer Res, 1999,5(3) :513-520.
3Peterson RM, Yu Q, Stamenkovic I, et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of muring mammary carcinoma cells in ascites[J] .Am J Pathol,2000, 156(6):2159-2167.
4Mori A, Arii S, Furutani M, et al. Soluble Fit- 1 gene therapy for peritoneal metastases using HVJ-cationic liposomes[J]. Gene Therapy, 2000,7(12):1027-1033.
5Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT- 1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer[J].Cancer Res, 2002,62(2):2019-2023.
7Schofield K, D'Aquila T, Rimm DL. E-cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens[J]. Diagn Cytopathol, 2000,22(5):263-267.
8Di Silverio F, Casale P, Colella D, et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell cacinoma[J]. Cancer, 2000,88(4) : 835-843.
6DeMay RM. The Art & Science of Cytopathology [M]. Chicago:ASCP Press, 1995:263-264.
7Ordonez NG. The immunohistochemical diagnosis of mesothelioma:differentiation of mesothelioma and lung adenocarcinoma [J]. Am J Surg Pathol, 1989, 13(4): 276-291.
8Kho-Duffin J, Tao LC, Cramer H, et al. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type [J]. Diagn Cytopathol, 1999, 20(2): 57-62.
9Fetsch PA, Abati A. lmmunocytochemistry in effusion cytology[J]. Cytopathology, 2001, 93 (5): 293-308.
10Behrens J. Cell contacts, differentiation, and invasiveness of epithelial cells [J]. Invasion Metastasis, 1994-95, 14 (1-6):61-70.
